Prostate & BPH Formulations

Tamsulosin Hydrochloride (0.4mg modified-release) and Dutasteride (0.5mg) Tablets/Capsules is a synergistic dual-action therapy on the WHO Model List framework for symptomatic Benign Prostatic Hyperplasia (BPH). Tamsulosin is a uroselective alpha-1A/1D adrenergic receptor antagonist that relaxes smooth muscle in the prostate stroma, prostatic capsule, and bladder neck, rapidly improving urinary peak flow rates and relieving lower urinary tract symptoms (LUTS). Dutasteride is a potent dual type 1 and type 2 5-alpha reductase inhibitor (5-ARI) that suppresses dihydrotestosterone (DHT) synthesis by >90%, progressively shrinking enlarged prostate volume over 3-6 months. Indicated for moderate-to-severe BPH with enlarged prostate (volume >30cc) to reduce the risk of acute urinary retention (AUR) and the need for BPH-related surgery (TURP).

Finasteride Tablets 5mg is an evidence-based dermatological formulation. It acts by delivering targeted active therapeutic ingredients to cutaneous lesions to relieve skin pathology, restore barrier integrity, and manage dermatoses.

Tamsulosin Hydrochloride Prolonged Release Capsules (0.4mg) is a uroselective alpha-1A and alpha-1D adrenergic receptor antagonist on the WHO Model List of Essential Medicines. By selectively blocking alpha-1A receptors concentrated in the human prostate, bladder neck, and prostatic urethra (which account for 70% of prostatic alpha receptors), it relaxes smooth muscle tone, reduces outflow resistance, and enhances maximum urinary flow rate (Qmax) with minimal effect on systemic vascular resistance. Indicated for symptomatic Benign Prostatic Hyperplasia (BPH) and as off-label medical expulsive therapy for distal ureteric stones.

Alfuzosin Prolonged-Release Tablets (10mg) is a quinazoline-derivative, functionally uroselective alpha-1 adrenergic antagonist on the WHO Model List framework. It distributes preferential clinical relaxant action to prostatic and trigonal smooth muscle, reducing bladder outlet obstruction without predominantly altering ejaculatory duct innervation, resulting in a very low incidence of retrograde ejaculation (<1-2%). Indicated for the treatment of moderate-to-severe symptoms of Benign Prostatic Hyperplasia (BPH) and as adjunctive therapy with catheterization for acute urinary retention related to BPH.

Alfuzosin (10mg prolonged-release) and Dutasteride (0.5mg) Tablets is a fixed-dose combination combining a functionally uroselective alpha-1 blocker with a dual 5-alpha reductase inhibitor. Alfuzosin relaxes prostatic smooth muscle and decreases bladder outlet resistance without inhibiting alpha-1A subtype exclusively, preserving normal ejaculation in most men. Dutasteride halts DHT-mediated androgenic proliferation, reducing prostate volume. Indicated for symptomatic BPH with enlarged prostate gland.

Dutasteride Capsules (0.5mg) is a synthetic 4-aza-steroid dual inhibitor of both type 1 and type 2 5-alpha-reductase isoenzymes on the WHO Model List of Essential Medicines. It blocks the enzymatic intracellular conversion of testosterone to 5-alpha-dihydrotestosterone (DHT) in the prostate, skin, and liver, suppressing circulating DHT levels by >90% and intraprostatic DHT by >94%. This induces apoptotic involution of prostatic epithelial cells, progressively reducing total prostate volume by ~25% and reducing risk of urinary retention and TURP surgery. Indicated for treatment of symptomatic BPH in men with enlarged prostate.

Finasteride Tablets 1mg is an evidence-based dermatological formulation. It acts by delivering targeted active therapeutic ingredients to cutaneous lesions to relieve skin pathology, restore barrier integrity, and manage dermatoses.

Silodosin Capsules (4mg, 8mg) is an ultra-selective alpha-1A adrenergic receptor antagonist on the PMBI formulary. It demonstrates an extraordinarily high alpha-1A to alpha-1B binding affinity ratio (162:1), targeting the lower urinary tract smooth muscle with surgical precision while sparing vascular alpha-1B receptors that regulate arterial blood pressure. This confers excellent cardiovascular safety and minimal postural hypotension. Indicated for the treatment of the signs and symptoms of Benign Prostatic Hyperplasia (BPH) in adult men.

Silodosin Capsules (4mg, 8mg) is an ultra-selective alpha-1A adrenergic receptor antagonist on the PMBI formulary. It demonstrates an extraordinarily high alpha-1A to alpha-1B binding affinity ratio (162:1), targeting the lower urinary tract smooth muscle with surgical precision while sparing vascular alpha-1B receptors that regulate arterial blood pressure. This confers excellent cardiovascular safety and minimal postural hypotension. Indicated for the treatment of the signs and symptoms of Benign Prostatic Hyperplasia (BPH) in adult men.

Silodosin (4mg/8mg) and Dutasteride (0.5mg) Capsules is an advanced fixed-dose combination for Benign Prostatic Hyperplasia (BPH). Silodosin is an ultra-selective alpha-1A adrenergic receptor antagonist (>160-fold selectivity over alpha-1B receptors), providing targeted bladder neck and prostatic relaxation with minimal vascular hypotensive effects. Dutasteride blocks both 5-alpha reductase isoforms, permanently lowering circulating and intraprostatic DHT to shrink prostate gland tissue. Indicated for treatment of moderate-to-severe LUTS associated with prostatic enlargement.

Silodosin (4mg/8mg) and Dutasteride (0.5mg) Capsules is an advanced fixed-dose combination for Benign Prostatic Hyperplasia (BPH). Silodosin is an ultra-selective alpha-1A adrenergic receptor antagonist (>160-fold selectivity over alpha-1B receptors), providing targeted bladder neck and prostatic relaxation with minimal vascular hypotensive effects. Dutasteride blocks both 5-alpha reductase isoforms, permanently lowering circulating and intraprostatic DHT to shrink prostate gland tissue. Indicated for treatment of moderate-to-severe LUTS associated with prostatic enlargement.

Tamsulosin Hydrochloride (0.4mg) and Tolterodine Tartrate (2mg/4mg Extended Release) Capsules is a fixed-dose combination for men suffering from mixed storage and voiding lower urinary tract symptoms (LUTS). Tamsulosin relieves voiding symptoms (hesitancy, weak stream, straining) via alpha-1A adrenergic blockade, while tolterodine competitively antagonizes muscarinic M2/M3 receptors in the detrusor muscle, abolishing involuntary bladder spasms and relieving storage symptoms (frequency, urgency, nocturia). Indicated for men with BPH and co-existing Overactive Bladder (OAB).

Tamsulosin Hydrochloride (0.4mg) and Tolterodine Tartrate (2mg/4mg Extended Release) Capsules is a fixed-dose combination for men suffering from mixed storage and voiding lower urinary tract symptoms (LUTS). Tamsulosin relieves voiding symptoms (hesitancy, weak stream, straining) via alpha-1A adrenergic blockade, while tolterodine competitively antagonizes muscarinic M2/M3 receptors in the detrusor muscle, abolishing involuntary bladder spasms and relieving storage symptoms (frequency, urgency, nocturia). Indicated for men with BPH and co-existing Overactive Bladder (OAB).

Deflazacort (30mg) and Tamsulosin (0.4mg) Tablets is a specialized medical expulsive therapy (MET) combination. Tamsulosin blocks alpha-1D receptors located predominantly in the lower third of the ureter and ureterovesical junction (UVJ), inhibiting ureteral smooth muscle spasm and dilating the ureteral lumen. Deflazacort is an oxazoline glucocorticoid that exerts potent anti-inflammatory and anti-edematous action around the impacted stone site, reducing localized mucosal swelling and pain. Indicated for medical expulsive therapy of distal ureteral calculi (stones measuring 5 to 10 mm) to accelerate spontaneous stone passage and reduce surgical intervention.